Cargando…

Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP

Detalles Bibliográficos
Autores principales:	Bewarder, Moritz, Kaddu-Mulindwa, Dominic, Kos, Igor Age, Lesan, Vadim, Held, Gerhard, Poeschel, Viola, Thurner, Lorenz, Bittenbring, Joerg Thomas, Schmitz, Norbert, Truemper, Lorenz, Pfreundschuh, Michael, Christofyllakis, Konstantinos, Loeffler, Markus, Altmann, Bettina, Ziepert, Marita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543194/ https://www.ncbi.nlm.nih.gov/pubmed/36815369 http://dx.doi.org/10.3324/haematol.2022.282126

Ejemplares similares

Vitamin D Enhances Immune Effector Pathways of NK Cells Thus Providing a Mechanistic Explanation for the Increased Effectiveness of Therapeutic Monoclonal Antibodies
por: Christofyllakis, Konstantinos, et al.
Publicado: (2023)

Advances in Lymphoma Molecular Diagnostics
por: Kos, Igor Age, et al.
Publicado: (2021)

Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives
por: Kaddu-Mulindwa, Dominic, et al.
Publicado: (2022)

PB2104: DOSE-DENSE CHEMOTHERAPY WITH R-CHOP-14 IN OLDER ADULTS AGED ≥80 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Christofyllakis, K., et al.
Publicado: (2022)

Ars2‐containing bispecific, Fab‐ and IgG1‐format BAR‐bodies to target DLBCL cells
por: Kiefer, Maximilian, et al.
Publicado: (2022)

Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group
por: Hohloch, Karin, et al.
Publicado: (2020)

FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
por: Kaddu-Mulindwa, Dominic, et al.
Publicado: (2021)

Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial
por: Held, Gerhard, et al.
Publicado: (2023)

Increased B‐cell activity with consumption of activated monocytes in severe COVID‐19 patients
por: Kos, Igor, et al.
Publicado: (2021)

The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells
por: Bewarder, Moritz, et al.
Publicado: (2021)

Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential
por: Bewarder, Moritz, et al.
Publicado: (2020)

Current Treatment Options in CLL
por: Bewarder, Moritz, et al.
Publicado: (2021)

IgG seroprevalence of COVID‐19 among people living with HIV or at high risk of HIV in south‐west Germany: A seroprevalence study
por: Kaddu‐Mulindwa, Dominic, et al.
Publicado: (2021)

Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019
por: Lesan, Vadim, et al.
Publicado: (2021)

Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study
por: Thurner, Lorenz, et al.
Publicado: (2023)

Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma
por: Bewarder, Moritz, et al.
Publicado: (2020)

Adjuvant Therapy of High-Risk (Stages IIC–IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis
por: Christofyllakis, Konstantinos, et al.
Publicado: (2021)

Protection strategy against outbreak of COVID-19 at a tertiary hematology-oncology: strengths and pitfalls
por: Kaddu-Mulindwa, Dominic, et al.
Publicado: (2021)

Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab
por: Kos, Igor, et al.
Publicado: (2020)

Indeterminate Dendritic Cell Tumor With Persistent Complete Metabolic Response to BRAF/MEK Inhibition
por: Thurner, Lorenz, et al.
Publicado: (2020)

MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians
por: Bittenbring, Joerg, et al.
Publicado: (2008)

Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma—data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin’s Lymphoma Study Group)
por: Zettl, Florian, et al.
Publicado: (2020)

CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial
por: Binder, C., et al.
Publicado: (2013)

Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma
por: Thurner, Lorenz, et al.
Publicado: (2020)

Liver stiffness as surrogate parameter in emergency assessment for inpatient health care utilization
por: Kaddu-Mulindwa, Dominic, et al.
Publicado: (2022)

The riddle of lymphoma BCR-antigenes
por: Thurner, Lorenz, et al.
Publicado: (2018)

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
por: Houot, Roch, et al.
Publicado: (2022)

B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma
por: Thurner, Lorenz, et al.
Publicado: (2023)

Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like Chemotherapy
por: Okada, Naoto, et al.
Publicado: (2014)

Fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in PLWH treated with modern ART: A prospective analysis
por: Kaddu-Mulindwa, Dominic, et al.
Publicado: (2022)

First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial
por: Braulke, Friederike, et al.
Publicado: (2022)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Landscape of 4D Cell Interaction in Hodgkin and Non-Hodgkin Lymphomas
por: Hartmann, Sylvia, et al.
Publicado: (2021)

Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL
por: Hohloch, Karin, et al.
Publicado: (2014)

Prevalence of Anti-Citrullinated Protein Antibodies (ACPA) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Case-Control Study
por: Assmann, Gunter, et al.
Publicado: (2014)

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis
por: Thieblemont, Catherine, et al.
Publicado: (2023)

Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
por: Lim, Kyu-Hyoung, et al.
Publicado: (2010)

Autoantibodies against SUMO1-DHX35 in long-COVID
por: Thurner, Lorenz, et al.
Publicado: (2022)

Role of Specific B-Cell Receptor Antigens in Lymphomagenesis
por: Thurner, Lorenz, et al.
Publicado: (2020)

Progranulin autoantibodies in systemic sclerosis and autoimmune connective tissue disorders: A preliminary study
por: Klemm, Philipp, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j6vm8301vl5vhv3i2lsc1u7hmp